What is InformedDNA?
InformedDNA operates as the preeminent authority on the appropriate utilization of genetic testing, maintaining the largest independent staff of board-certified genetics specialists in the United States. The company provides a comprehensive suite of services, including clinical genetic counseling, genetic testing utilization management, and payment integrity solutions. By acting as a neutral intermediary, InformedDNA assists health systems and employers in navigating the complexities of genomic diagnostics, thereby reducing unnecessary testing costs while improving patient care standards. Their expertise is increasingly vital as precision medicine becomes a standard component of modern healthcare delivery, requiring rigorous oversight and expert interpretation to ensure clinical efficacy.
How much funding has InformedDNA raised?
InformedDNA has raised a total of $22.2M across 4 funding rounds:
Private Equity
$7.7M
Unspecified
$3M
Private Equity
$5M
Private Equity
$6.5M
Private Equity (2013): $7.7M, investors not publicly disclosed
Unspecified (2013): $3M led by MPM Capital
Private Equity (2014): $5M supported by Zaffre Investments, LLC.
Private Equity (2016): $6.5M, investors not publicly disclosed
Key Investors in InformedDNA
MPM Capital
MPM BioImpact manages early-stage venture funds and private impact funds, focusing on converting scientific innovation into viable therapeutics for patients.
Zaffre Investments, LLC.
A subsidiary of Blue Cross Blue Shield of Massachusetts, this firm invests in healthcare technologies and services that improve delivery models, with a focus on health information technology and consumer solutions.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for InformedDNA?
With the support of its strategic investment partners, InformedDNA is well-positioned to capitalize on the accelerating demand for genomic data integration in clinical trials and population health management. The company's roadmap likely involves deepening its technological infrastructure to support automated utilization management and expanding its footprint in the pharmaceutical sector, where genetic insights are essential for patient stratification and drug development. As the regulatory environment for genetic testing evolves, InformedDNA's role as a gatekeeper and expert consultant will be pivotal in maintaining quality control and cost-efficiency across the healthcare ecosystem. Future growth will likely focus on scaling its digital counseling platforms to meet the rising volume of genetic testing requests globally.
See full InformedDNA company page
